NEWS 10 November 2021 Sonendo's GentleWave Surpasses 700,000 Treatments, Solidifying Procedure as Alternative to Traditional Root Canal Therapy Sonendo, Inc., (NYSE: SONX) a leading dental technology company and developer of the GentleWave® System, today announced it has treated over 700,000 patients with its GentleWave® System, an alternative to traditional root canal therapy (RCT) backed by years of research and peer-reviewed clinical outcomes. This milestone comes after the company's recent IPO on October 29, 2021. 28 October 2021 Sonendo, Inc. Announces Pricing of Initial Public Offering Sonendo, Inc., a leading dental technology company and developer of the GentleWave® System, today announced the pricing of its initial public offering of 7,800,000 shares of its common stock at a public offering price of $12.00 per share, for total gross proceeds of $93.6 million, before deducting underwriting discounts and commissions and estimated offering expenses. All of the shares are being offered and sold by Sonendo. Sonendo’s common stock is expected to begin trading on the New York Stock Exchange on October 29, 2021, under the ticker symbol "SONX." The offering is expected to close on November 2, 2021, subject to the satisfaction of customary closing conditions. In addition, Sonendo has granted the underwriters a 30-day option to purchase up to an additional 1,170,000 shares of common stock at the initial public offering price, less the underwriting discounts and commissions. 25 October 2021 Sonendo, Inc. Announces Launch of Initial Public Offering Sonendo, Inc. (“Sonendo”), a leading dental technology company and developer of the GentleWave® System, today announced that it has launched the roadshow for its initial public offering of shares of its common stock. Sonendo is offering 7,800,000 shares of its common stock. In addition, Sonendo expects to grant the underwriters a 30-day option to purchase up to an additional 1,170,000 shares of its common stock. The initial public offering price is expected to be between $15.00 and $17.00 per share. The shares are expected to trade on the New York Stock Exchange under the symbol “SONX.” 18 October 2021 Immunocore and Medison Pharma Partner for Future Commercialization of Tebentafusp in Canada, Central Eastern Europe, and Israel Immunocore (Nasdaq: IMCR), a late-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infection and autoimmune disease, and Medison Pharma Ltd., a global pharma company focused on providing access to highly innovative therapies to patients in international markets, today announced an exclusive multi-regional agreement for Medison to help seek regulatory authorization and commercialize Immunocore’s tebentafusp (IMCgp100), for the treatment of patients with metastatic uveal melanoma, in Canada, twenty markets across Central Eastern Europe and Israel. 14 October 2021 JenaValve Announces First European Commercial Implants with the Trilogy™ Heart Valve System JenaValve Technology, Inc., developer and manufacturer of differentiated transcatheter aortic valve replacement (TAVR) systems, today announced the first commercial implants with the Trilogy Heart Valve System in Europe. The procedures, which included treatment of both aortic regurgitation1 (AR) and aortic stenosis1 (AS), took place in multiple centers in Germany, marks the official start of the European commercial launch of Trilogy. < Previous1234567...115Next > ABOUT STRATEGY TEAM PORTFOLIO NEWS CONTACT Neomed Management AS © 2014 All Rights Reserved. Design by: Designcontainer